



Span Divergent Ltd.
(Formerly Span Diagnostics Ltd.)
9th Floor, Rajhans Bonista,
Behind Ram Chowk, Ghod Dod Road,
Surat - 395 007, Gujarat, India
Phone: +91 261 266 32 32
E-Mail: contact@span.in

Date: October 29, 2024

**To,
Listing Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Tower, 25th Floor
Dalal Street, Mumbai – 400 001**

Respected Sir,

**Subject: Unaudited Financial Results for the Quarter and Half Year ended on September 30, 2024
Scrip Code: 524727**

We are pleased to forward herewith Unaudited Financial Results (Both Standalone Financial Results & Consolidated Financial Results) of the Company for the quarter and half year ended on September 30, 2024 along with Limited Review Reports (Both Standalone Financial Results & Consolidated) in compliance with the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said financial results have been approved by Board of Directors at their meeting held on October 28, 2024.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

For Span Divergent Limited

**Viral P Desai
Managing Director
DIN 00021929**

Encl: As above

CIN: L74999GJ1980PLC003710

www.span.in

SPAN DIVERGENT LIMITED
Half Yearly Standalone Financial Results-FY-2024-25

Span Divergent Limited
(Formerly known as Span Diagnostics Limited)
Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007
CIN:L74999GJ1980PLC003710 Website: www.span.in
Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2024.
(Rs. In Lakhs except per share data)

Standalone							
Sr. No.	Particulars	Three Months			Six Months		Year ended 31 March 2024
		Quarter ended 30 September 2024	Quarter ended 30 June 2024	Quarter ended 30 September 2023	Half Year ended 30 September 2024	Half Year ended 30 September 2023	
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	
1	Income from operations						
	Other Operating Income	43.42	51.28	46.41	94.70	94.56	191.45
	Other income	26.41	22.26	20.03	48.68	42.01	154.98
	Total income	69.83	73.54	66.44	143.38	136.58	346.43
2	Expenses						
	Employee benefit expense	29.46	26.41	28.71	55.87	57.00	117.50
	Finance costs	-	-	-	-	-	-
	Depreciation and amortisation expense						
	Other expenses	6.29	6.31	8.75	12.60	17.44	34.11
	9.33	9.33	9.38	11.38	18.71	21.32	51.89
	Total expenses	45.07	42.10	48.84	87.18	95.77	203.51
3	Profit / (Loss) before exceptional items, Prior Period items and tax (1-2)	24.76	31.44	17.60	56.20	40.81	142.92
4	Exceptional items (Refer Note 5)	-	2.00	-	2.00	-	8.50
5	Profit/(Loss) before tax (3-4)	24.76	33.44	17.60	58.20	40.81	151.41
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	0.59	10.36	1.20	10.94	(3.31)	0.43
7	Profit/(Loss) for the period after tax (5-6)	24.17	23.08	16.40	47.26	44.12	150.98
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of Income tax relating to items that will not be reclassified to Profit or Loss	(0.40)	(0.40)	(0.42)	(0.80)	(0.85)	(1.59)
	0.11	0.11	0.11	0.12	0.22	0.24	0.44
9	Total comprehensive income for the year (7+8)	23.90	22.79	16.10	46.68	43.51	149.83
10	Paid-up equity share capital (Face value of Rs. 10/- each)	546.17	546.17	546.17	546.17	546.17	546.17
11	Other Equity						2,865.89
	Earnings per equity share for profit from operation attributable to owners of the entity:						
12	Basic earnings per share	0.44	0.42	0.30	0.87	0.81	2.76
13	Diluted earnings per share	0.44	0.42	0.30	0.87	0.81	2.76



Note : -		
1. Statement of Assets and Liabilities as at September 30, 2024 and March 31, 2024 is given below:		
Rs. In Lakh		
Particulars	Standalone	
	As at September 30, 2024	As at March 31, 2024
Non-current assets		
Property, plant and equipment	313.61	320.67
Capital Work In Progress	-	-
Right-of-use-assets	3.83	8.42
Investment properties	-	-
Goodwill	-	-
Other intangible assets	1.80	2.19
Intangible assets under development	-	-
Biological assets other than bearer plants	-	-
Financial assets	-	-
i. Investments Non-current assets	2,882.27	2,853.09
ii. Others	45.78	50.08
ii. Loans Non-current assets	-	-
iii. Others Non-current assets	-	-
Deferred tax assets (Net)	8.02	9.67
Other non-current assets	-	-
Total non-current assets	3,255.31	3,244.11
Current assets		
Financial assets		
i. Investments Current assets	573.65	468.56
ii. Trade receivables Current assets	25.01	19.05
iii. Cash and cash equivalents	3.21	37.78
iv. Bank balances other than (iii) above	-	-
v. Loans Current assets	-	-
v. Others Current assets	9.21	10.65
Current tax Assets (Net)	70.16	65.03
Other current assets	3.27	0.87
Assets classified as held for sale	-	-
Total current assets	684.50	601.94
TOTAL	3,939.81	3,846.06
EQUITY AND LIABILITIES		
Equity		
Equity share capital/Partners capital	546.17	546.17
Other equity	2,939.76	2,865.89
Total equity	3,485.92	3,412.07
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
i. Borrowings Non-current liabilities	197.20	197.70
ii. Lease Liabilities	-	-
iii. Other financial liabilities Non-current liabilities	-	-
Provisions Non-current liabilities	35.07	33.25
Deferred tax liabilities (Net)	26.23	17.15
Total non-current liabilities	258.50	248.10
Current liabilities		
Financial liabilities		
i. Borrowings Current liabilities	-	-
ii. Lease liabilities	4.85	10.46
iii. Trade payables Current liabilities	-	-
A) total outstanding dues of micro enterprises and small enterprises; and	0.75	-
B) total outstanding dues of creditors other than micro enterprises and small enterprises	5.02	1.67
iv. Other financial liabilities Current liabilities	150.10	135.86
Other current liabilities	3.76	5.39
Provisions Current liabilities	30.90	32.51
Current tax liabilities	-	-
Total current liabilities	195.39	185.88
TOTAL	3,939.81	3,846.06



- 2 Figures for the quarter ended September 30, 2024 are the balancing figures between the reviewed figures till September 30, 2024 and reviewed figures up to the first quarter of the relevant financial year.
- 3 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2024.
- 4 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 28, 2024.
- 5 Other Operating Income comprises of Interest on fluctuating capital provided by the Company to its LLP subsidiaries and management fees income which is based on the revenue earned by subsidiaries during the period.
- 6 In case of subsidiary:
 - (a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.10 Crores till March 31 2024 and Rs. 0.02 crore in the current year up to September 30, 2024. In light of the accumulated losses and business scenario going forward, Board has approved the plan for discontinuation of operations of the LLP and the Assets of the LLP have been classified as Asset held for sale w.e.f September 30, 2023.
 - (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
 - (c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs.6.17 Crores till September 30, 2024. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.07 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive by 2025.
- 7 Previous periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited



Viral Desai

Managing Director

DIN : 00029219

Place : Surat

Date : October 28, 2024



Span Divergent Limited standalone

8. Statement of Cash Flows for the Period Ended September 30, 2024

Particular	Half Year ended 30 September 2024	Year ended 31 March 2024
Profit before income tax	58.20	151.42
Adjustments for		
Depreciation and amortisation expense	12.60	34.11
Intangible Assets Written Off	-	-
Un realised Loss/(Gain) on Investments	(19.16)	(28.86)
Dividend and interest income classified as investing cash flows	-	-
Rental Income	(24.27)	(47.98)
Interest Income	(2.26)	(3.78)
Gain on Sale of Investments	18.27	28.62
Gain on Sale of Assets	0.05	(69.67)
Finance Cost	-	-
Financial Guarantee Fees Income	(2.10)	(3.95)
Balances Written Back	-	-
Impairment Provision for LLP Subsidiaries	(2.00)	(8.50)
Rental Expense	-	-
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	(5.96)	(2.73)
Increase in trade payables	4.10	(4.55)
(Increase) in other financial assets	1.44	5.62
(Increase)/decrease in other non-current assets	4.30	(2.77)
(Increase)/decrease in other current assets	(2.40)	17.70
Increase/(decrease) in provisions	0.79	7.49
Increase/(decrease) in other financial liabilities	14.24	(5.11)
Increase in other current liabilities	(7.23)	(8.97)
Cash generated from operations	48.60	58.07
Income taxes paid	(22.07)	4.86
Net cash inflow from operating activities	70.66	53.20
Cash flows from investing activities		
(Purchase)/Redemption of investments in Subsidiary	(27.18)	(53.04)
Proceeds from sale of investments	(105.10)	(74.02)
Investment in Fixed Deposits for more than one year	4.30	(2.77)
(Purchase)/Sale of property, plant and equipment	(0.61)	90.00
Dividends received	-	-
Rental Income	24.27	47.98
Interest received	(0.44)	7.73
Net cash outflow from investing activities	(104.76)	15.87
Cash flows from financing activities		
Proceeds/(Repayment to) from borrowings	(0.50)	(56.30)
Payment towards unclaimed dividend	-	-
Interest paid	-	-
Net cash inflow (outflow) from financing activities	(0.50)	(56.30)
Net increase (decrease) in cash and cash equivalents	(34.57)	12.79
Cash and cash equivalents at the beginning of the financial year	37.78	24.99
Cash and cash equivalents at end of the year	3.20	37.78
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
Particulars	Half Year ended 30 September 2024	Year ended 31 March 2024
Balances with banks		
- in current accounts	3.14	37.73
Cash on hand	0.06	0.05
Balances per statement of cash flows	3.20	37.78



SPAN DIVERGENT LIMITED
Half Yerly consolidated Financial Results - FY - 2024:25

Span Divergent Limited (Formerly known as Span Diagnostics Limited) Regd. Office : 9th Floor, 902-904, Rajhans Bonista, Behind Ram Chowk Temple, Ghod Dod Road, Surat-395007 CIN:L74999GJ1980PLC003710 Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024.							
Sr. No.	Particulars	Consolidated					Year ended 31 March 2024
		Three Months			Six Months		
		Quarter ended 30 September 2024	Quarter ended 30 June 2024	Quarter ended 30 September 2023	Six Months ended 30 September 2024	Six Months ended 30 September 2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Income from operations						
	Sale of Traded Products/Services	269.33	352.25	277.20	621.58	603.13	1,169.01
	Other Operating Income	11.25	18.75	9.02	30.00	25.52	64.25
	Other income	24.73	17.52	27.43	42.25	45.30	169.23
	Income from Discontinued operations	-	-	32.47	-	32.47	32.47
	Total income	305.31	388.52	346.12	693.83	706.42	1,434.96
2	Expenses						
	Cost of materials consumed	-	-	-	-	-	0.09
	Purchases of stock-in-trade	16.62	92.58	7.47	109.20	40.87	171.67
	Changes in inventories of work-in-progress, stock-in-trade and finished goods	9.66	46.19	26.31	55.85	59.60	36.80
	Employee benefit expense	62.07	52.51	54.86	114.58	105.57	229.50
	Finance costs	15.29	16.22	18.04	31.51	36.88	71.91
	Depreciation and amortisation expense	28.43	28.18	47.32	56.61	96.80	164.45
	Other expenses	167.55	152.65	209.47	320.20	377.98	689.18
	Total expenses	299.62	388.33	363.47	687.94	717.70	1,363.60
3	Profit / (Loss) before tax and Exceptional items (1-2)	5.69	0.19	(17.35)	5.89	(11.28)	71.36
4	Exceptional items	-	2.00	0.01	2.00	0.01	8.50
5	Profit/(Loss) before tax (3-4)	5.69	2.19	(17.34)	7.89	(11.27)	79.86
6	Tax expense:						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	1.04	10.72	12.71	11.76	5.73	1.80
7	Profit/(Loss) for the period after tax (5-6)	4.65	(8.53)	(30.05)	(3.87)	(17.00)	78.06
	Profit for the year attributable to:						
	(a) Owners of the Company	12.64	(0.55)	(26.36)	12.10	(6.79)	97.55
	(b) Non Controlling Interest	(7.99)	(7.98)	(3.68)	(15.97)	(10.20)	(19.50)
		4.65	(8.53)	(30.05)	(3.87)	(16.99)	78.05
8	Other comprehensive income						
	Item that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liabilities)	0.39	0.39	(0.12)	0.79	(0.24)	1.58
	Income tax relating to items that will not be reclassified to Profit or Loss	(0.15)	(0.15)	0.02	(0.30)	0.04	(0.59)
	Other comprehensive income	0.25	0.24	(0.10)	0.49	(0.20)	0.99
	Other comprehensive income attributable to:						
	(a) Owners of the Company	0.30	0.29	0.44	0.61	0.37	(2.52)
	(b) Non Controlling Interest	(0.06)	(0.06)	0.08	(0.12)	0.05	3.50
		0.25	0.24	0.52	0.49	0.42	0.98
9	Total comprehensive income for the year (7+8)	4.89	(8.29)	(30.15)	(3.38)	(17.20)	79.05
	Total comprehensive income attributable to:						
	(a) Owners of the Company	12.83	(0.37)	(26.49)	12.48	(7.05)	95.04
	(b) Non Controlling Interest	(7.93)	(7.92)	(3.66)	(15.86)	(10.15)	(15.99)
		4.89	(8.29)	(30.15)	(3.38)	(17.20)	79.04
10	Paid-up equity share capital (Face value of Rs. 10/- each)	546.17	546.17	546.17	546.17	546.17	546.17
11	Other Equity						(734.91)
	Earnings per equity share for profit from operation attributable to owners of the entity:						
12	Basic earnings per share *	0.09	(0.16)	(0.55)	(0.07)	(0.31)	1.43
13	Diluted earnings per share *	0.09	(0.16)	(0.55)	(0.07)	(0.31)	1.43

* For the period only and not annualised



SPAN DIVERGENT LIMITED
Half Yerly consolidated Financial Results - FY - 2024:25

Note

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 28, 2024.
- 2 As required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have conducted a limited review of the above results for the quarter ended September 30, 2024.
- 3 The financial results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the relevant rules of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the
- 4 In case of subsidiary:
 - (a) Aranya Agri Biotech LLP had accumulated losses of Rs. 15.10 Crores till March 31 2024 and Rs. 0.02 crore in the current year up to September 30, 2024. In light of the accumulated losses and business scenario going forward, Board has approved the plan for discontinuation of operations of the LLP and the Assets of the LLP have been classified as Asset held for sale at w.e.f September 30, 2023.
 - (b) Biospan Scientific LLP had accumulated losses of Rs.1.57 Crores as at 31st March 2019, resulting in substantial erosion of the net worth of the LLP. Hence the Management had decided to impair the investment and Rs. 1.83 Crores were provided in the books of the Company and was treated as an exceptional item during the year 2018-19. Notwithstanding the above, the financial results of the LLP has been prepared on going concern basis as Management is exploring the possibilities to revive the LLP on its own or by entering in to business tie-ups and it endeavours to be able to establish profitable operation.
 - (c) Biospan Contamination Control Solution Pvt. Ltd had accumulated losses of Rs.6.17 Crores till September 30, 2024. As on that date the subsidiary Company's total liabilities exceeded its total assets by Rs. 6.07 Crores. Notwithstanding the above, the financial results of the subsidiary Company has been prepared on going concern basis as Management believes that the company would be able to establish profitable operation and the losses incurred is attributable to factors of temporary nature. Further, Management is confident that with appropriate product introductions, the Company will achieve adequate revenue and negative net worth would turn positive by 2025.
- 5 In pursuance to Section 115BAA of the Income Tax Act, 1961 announced by Government of India through Taxation Laws (Amendment) Ordinance, 2019, the Company has an irrevocable option of shifting to a lower tax rate along with consequent reduction in certain tax incentive including additional depreciation and accumulated depreciation in any subsequent year(s). The Company is evaluating this option and continues to recognise the taxes on income for the quarter and period ended September 30, 2024 as per the earlier provisions.
- 6 Previous quarters and periods figures have been regrouped and rearranged wherever necessary.

For, Span Divergent Limited


Viral Desai
Managing Director
DIN: 00029219

Place : Surat

Date : October 28, 2024



SPAN DIVERGENT LIMITED*(Formerly known as Span Diagnostics Limited)***7. Consolidated Balance Sheet at the Half Year ended September 30, 2024.**

Particulars	As at September 30, 2024	As at March 31, 2024
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	990.63	1,038.79
Right-of-use-assets	(9.10)	33.90
Investment properties	-	-
Goodwill	-	-
Intangible assets	1.81	2.19
Intangible assets under development	-	-
Biological assets other than bearer plants	-	-
Financial assets	-	-
i. Investments	-	-
ii. Trade Receivables	-	-
ii. Loans	-	-
i. Others	45.78	50.08
Deferred tax assets (Net)	38.77	41.59
Other non-current assets	-	-
Assets classified as held for sale	43.03	45.15
Total non-current assets	1,110.93	1,211.70
Current assets		
Inventories	61.71	118.20
Financial assets	-	-
i. Investments	618.79	468.56
ii. Trade receivables	138.74	155.48
iii. Cash and cash equivalents	42.68	92.51
iv. Bank balances other than (iii) above	-	-
v. Others	22.38	32.10
vi. Other Financial Assets	-	-
Current tax Assets (Net)	97.93	84.00
Other current assets	239.49	256.14
Assets classified as held for sale	-	-
Total current assets	1,221.71	1,206.99
Total assets	2,332.64	2,418.69
EQUITY AND LIABILITIES		
Equity		
Equity share capital	546.17	546.17
Other equity	(695.26)	(734.91)
Non Controlling Interest	(583.88)	(568.03)
	(732.96)	(756.77)
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
i. Borrowings	294.34	341.41
ii. Lease Liability	-	22.13
Provisions	52.45	48.65
Deferred tax liabilities (Net)	41.85	32.61
Other non-current liabilities	28.34	29.84
Total non-current liabilities	416.98	474.64
Current liabilities		
Financial liabilities		
i. Borrowings	509.24	517.77
ii. Lease liabilities	4.85	29.92
iii. Trade payables	-	-
A) total outstanding dues of micro enterprises and small enterprises; and	5.74	25.36
B) total outstanding dues of creditors other than micro enterprises and small enterprises	264.89	250.10
iv. Other financial liabilities	166.08	152.76
Other current liabilities	6.62	29.45
Provisions	1,691.20	1,695.46
Total current liabilities	2,648.62	2,700.82
Total liabilities	3,065.60	3,175.46
Total equity and liabilities	2,332.64	2,418.69



(Handwritten signature/initials)

8. Consolidated Cash Flow Statement as at September 30, 2024		
Particulars	As at 30 September 2024	As at 31 March 2024
Profit before income tax	7.89	79.86
Adjustments for		
Depreciation and amortisation expense	56.61	164.45
Intangible Asset Written off	-	-
Capital Assets Write off	-	19.19
Dividend and interest income classified as investing cash flows	-	-
Rental Income	(24.27)	(47.98)
Interest Income	(2.26)	(6.11)
Gain on Sale of Investments	(0.93)	(69.91)
Unrealised Gain Loss on Biological Assets/Investments	-	-
Finance Cost	31.51	71.91
Balances Written Back	-	9.88
(Gain)/Loss on Sale property, plant and equipment	0.05	13.84
Impairment of Investments	(2.00)	(8.50)
Change in operating assets and liabilities:		
(Increase)/Decrease in trade receivables	16.74	34.44
(Increase)/Decrease in Inventory	56.50	42.35
(Increase)/Decrease in Biological Assets	-	-
Increase in trade payables	(4.82)	8.22
(Increase) in other financial assets	14.02	1.03
(Increase)/decrease in other non-current assets	-	0.11
(Increase)/decrease in other current assets	16.65	4.70
Increase/(decrease) in provisions	4.41	0.89
Increase/(decrease) in other financial liabilities	13.32	(26.18)
Increase in other current liabilities	(71.52)	(38.22)
Cash generated from operations	111.88	253.97
Income taxes paid	13.26	(3.70)
Net cash inflow from operating activities	125.14	250.27
Cash flows from investing activities		
Proceeds / (Purchase) from sale of investments	(149.30)	(4.11)
Purchase of property, plant and equipment	-	-
Proceeds from sale/(Purchase) of property, plant and equipment	34.89	(38.25)
Rental Income	24.27	47.98
Interest received	2.26	6.11
Net cash outflow from investing activities	(88)	11.72
Cash flows from financing activities		
Proceeds/Repayment from borrowings	(55.59)	(137.47)
Payment towards unclaimed dividend	-	-
Interest paid	(31.51)	(71.91)
Net cash inflow (outflow) from financing activities	(87)	(209.38)
Net increase (decrease) in cash and cash equivalents	(50)	52.61
Cash and cash equivalents at the beginning of the financial year	92.51	39.90
Cash and cash equivalents at end of the year	42.68	92.51
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
	As at 30 September 2024	As at 31 March 2024
Balances with banks and Cash on hand	42.68	92.51
Balances per statement of cash flows	42.68	92.51



9. Consolidated Segment Revenue, Results Assets and Liability as at September 30, 2024. (Rs. In Lakhs)

Sr. No.	Particulars	Three Months			Six Months		Year ended 31 March 2024
		Quarter ended 30 September 2024	Quarter ended 30 June 2024	Quarter ended 30 September 2023	Half Year Ended 30 September 2024	Half Year Ended 30 September 2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Segment Revenue						
	- Cashew processing	238.75	276.77	252.84	515.51	486.03	929.46
	- Tissu Culture	-	-	34.28		46.01	46.49
	- Trading	55.68	77.21	30.69	110.51	113.51	263.67
	Gross Revenue from Operations from Segments	294.43	353.97	317.80	626.02	645.56	1,239.62
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Revenue from Operations from Segments	294.43	353.97	317.80	626.02	645.56	1,239.62
2	Segment Results						
	Profit / (Loss) before Interest and tax						
	- Cashew processing	9.16	(23.22)	(9.76)	(14.06)	(23.52)	(21.46)
	- Tissu Culture	-	(1.28)	(22.95)	-	(26.93)	(30.40)
	- Trading	7.83	(6.72)	(2.45)	(35.52)	(2.06)	(20.49)
	- Unallocable Income over expenses like (Including HO)	(11.30)	33.39	17.83	38.31	41.24	152.21
	Total Profit / (Loss) before Tax	5.69	2.17	(17.34)	(11.27)	(11.27)	79.86
3	Segment Assets						
	- Cashew processing	1,034.00	1,015.21	1,196.00	1,034.00	1,196.00	1,081.75
	- Tissu Culture	94.83	47.93	99.30	94.83	99.30	97.43
	- Trading	188.30	214.08	225.27	188.30	225.27	240.37
	- Unallocable	1,015.50	5,617.43	883.36	1,015.50	883.36	999.15
	Total Assets	2,332.64	6,894.65	2,403.94	2,332.64	2,403.94	2,418.70
4	Segment Liability						
	- Cashew processing	349.79	743.75	592.92	349.79	592.92	429.21
	- Tissu Culture	29.66	132.21	29.30	29.66	29.30	28.28
	- Trading	663.07	676.28	641.32	663.07	641.32	679.80
	- Unallocable	2,023.08	2,182.95	1,993.39	2,023.08	1,993.39	2,038.17
	Total Liability	3,065.60	3,735.19	3,256.93	3,065.60	3,256.93	3,175.47

For, Span Divergent Limited



Viral Desai
Managing Director
DIN: 00029219

Place : Surat

Date : October 28, 2024





**Independent Auditor's Review Report on the Quarterly and Year to Date
Unaudited Standalone Financial Results of the Company Pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended**


Review Report to
To the Board of Directors of
Span Divergent Ltd.

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Span Divergent Limited** ("the Company") for the quarter ended **September 30, 2024** and year to date from April 01, 2024 to September 30, 2024 (the "statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W**



**Mayank Y. Desai
Partner
Membership No. :- 108310**



UDIN: 24108310BKALUQ9554

Date :- 28th October, 2024

Place :-Surat



Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report to
The Board of Directors
Span Divergent Ltd.

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Span Divergent Limited** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended September 30, 2024 and year to date from **April 01, 2024 to September 30, 2024** (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including (the "Listing Regulation").
2. This Statement, which is the responsibility of the Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent Company:

- i. Span Divergent Limited



Subsidiary:

- Dryfruit Factory LLP
- Aranya Agri Biotech LLP
- Desai Farmharvest LLP
- Span Diagnostics LLP
- Biospan Scientific LLP
- Biospan Contamination Control Solutions Pvt Ltd

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information, in respect of subsidiary have been reviewed by their respective independent auditor.

The independent auditor's reports on interim financial results of this entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary, is based solely on the report of such auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of above matter is not modified with respect to our reliance on the work done and the reports of the other auditor.

**For Y. B. Desai and Associates
Chartered Accountants
Firm Registration No. 102368W**



**Mayank Y. Desai
Partner**

Membership No. :- 108310



UDIN: 24108310BKALUR9968

Date :- 28th October, 2024

Place :-Surat